Immunome (IMNM) Accumulated Expenses (2019 - 2026)

Immunome has reported Accumulated Expenses for 8 years, with the latest figure at $21.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 630.97% year-over-year to $21.9 million; the trailing twelve-month figure through Mar 2026 stood at $21.9 million (up 630.97% YoY), and the FY2025 full-year result was $41.7 million, up 25.54% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $21.9 million, down from $41.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $41.7 million in Q4 2025, with the low at $842000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $10.5 million across 5 years, with a median of $4.2 million in 2022.
• Annual changes were most pronounced in 2024 — Accumulated Expenses tumbled 68.78% — and 2025, when it jumped 674.25%.
• Immunome's Accumulated Expenses stood at $4.9 million in 2022, then soared by 62.75% to $8.0 million in 2023, then jumped by 313.42% to $33.2 million in 2024, then increased by 25.54% to $41.7 million in 2025, then plunged by 47.47% to $21.9 million in 2026.
• The last three Accumulated Expenses figures came in at $21.9 million (Q1 2026), $41.7 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.